Abstract
For the ultimate aim of preventing intestinal disability in inflammatory bowel disease (IBD), the treatment goal has moved from symptom control towards inflammation control (i.e., 'deep remission'). Furthermore, the concept of 'treat-to-target' has been adopted to assist in treatment escalation and better control. Although deep remission is possible with current biologics, there are still unmet needs in IBD management. Biosimilars of several biologics will be an increasingly common option in the near future. In this review, we review the current status of novel drugs for IBD, focusing on recent phase 2 and 3 randomized controlled trials, and address the issues of biosimilars. Recent studies of the 'treat-to-target' strategy and therapeutic drug monitoring are summarized.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
